Abstract

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, necessitating the continual refinement of therapeutic strategies. Pharmacogenomics, the study of how an individual’s genetic makeup influences drug response, has emerged as a promising avenue for achieving personalized cardiovascular medicine. This review provides a comprehensive overview of the effect of pharmacogenomics drugs on the cardiovascular system. Additionally, the review explores the impact of pharmacogenomics on other cardiovascular drugs, including ACE inhibitors and antiarrhythmic. The integration of genetic information into clinical decision-making processes offers the potential for more precise and individualized cardiovascular care.